5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes

    May 2015 in “ Endocrinology
    Maryam Nasiri, Nikolaos Nikolaou, Silvia Parajes, Nils Krone, George Valsamakis, George Mastorakos, Beverly Hughes, Angela E. Taylor, Iwona Bujalska, Laura Gathercole, Jeremy Tomlinson
    TLDR Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
    The study investigated the role of 5α-reductase type 2 (SRD5A2) in regulating glucocorticoid and androgen action on lipid metabolism in human hepatocytes, involving primary cells from 8 donors. It found that SRD5A2 influenced glucocorticoid metabolism, affecting liver cell metabolic phenotype. Androgens increased lipogenesis, with testosterone enhancing it in females but not males, while dihydrotestosterone decreased it in females. Glucocorticoids decreased lipogenesis dose-dependently but increased insulin-stimulated lipogenesis. Overexpression of SRD5A2 reduced cortisol's suppression of lipogenesis, an effect reversed by finasteride and dutasteride. The study suggested SRD5A2 as a potential target for metabolic disorder therapies and raised concerns about 5α-reductase inhibitors' impact on liver metabolism.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 161 results

    Similar Research

    5 / 1000+ results